- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BETTER THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,115 | +1,14 % | SANGAMO THERAPEUTICS, INC - 10-K/A, Annual Report | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| IBIO | 1,511 | +9,18 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 | ||
| TRAWS PHARMA | 1,305 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,900 | 0,00 % | Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | Unity Biotechnology, Inc. - 15-12G, Securities registration termination | ||
| CARTESIAN THERAPEUTICS | 5,350 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,060 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| ERASCA | 9,080 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| QIAGEN | 28,675 | +0,58 % | Dax klettert am Mittag ins Plus - RWE profitiert, Qiagen unter Druck | Frankfurt/Main - Der Dax ist am Dienstag nach einem negativen Start in den Handelstag bis zum Mittag leicht ins Plus geklettert. Gegen 12:30 Uhr wurde der Leitindex mit rund 24.115 Punkten berechnet... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,350 | 0,00 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BEAM THERAPEUTICS | 29,390 | 0,00 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ADMA BIOLOGICS | 10,600 | 0,00 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| APOGEE THERAPEUTICS | 82,03 | 0,00 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters | ||
| COGENT BIOSCIENCES | 35,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen |
Das Unternehmen BETTER THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BETTER THERAPEUTICS INC finden Sie auf Wallstreet Online.